[1] Kowdley KV, Brown KE, Ahn J, et al. ACG clinical guideline:
hereditary hemochromatosis[J]. Am J Gastroenterol, 2019,
114(8):1202-1218. DOI: 10.14309/ajg.0000000000000315.
[2] Olynyk JK, Ramm GA. Hemochromatosis[J]. N Engl J Med,
2022, 387(23):2159-2170. DOI: 10.1056/NEJMra2119758.
[3] Turshudzhyan A, Wu DC, Wu GY. Primary non-HFE
hemochromatosis: a review[J]. J Clin Transl Hepatol, 2023,
11(4):925-931. DOI: 10.14218/JCTH.2022.00373.
[4] 中华医学会肝病学分会 . 中国遗传性血色病诊疗指南[J]. 中
华肝 脏 病 杂 志 , 2024, 32(9): 787-798. DOI: 10.3760/cma.j.
cn501113-20240712-00319.
[5] Lv TX, Zhang W, Xu AJ, et al. Non-HFE mutations in
haemochromatosis in China: combination of heterozygous
mutations involving HJV signal peptide variants[J]. J Med
Genet, 2018, 55(10):650-660. DOI: 10.1136/jmedgenet-2018-
105348.
[6] Zhang W, Xu AJ, Li Y, et al. A novel SLC40A1 p. Y333H
mutation with gain of function of ferroportin: a recurrent
cause of haemochromatosis in China[J]. Liver Int, 2019, 39(6):
1120-1127. DOI: 10.1111/liv.14013.
[7] Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and
management of hemochromatosis: 2011 practice guideline by
the American Association for the Study of Liver Diseases[J].
Hepatology, 2011, 54(1):328-343. DOI:10.1002/hep.24330.
[8] Nemeth E, Ganz T. Hepcidin and iron in health and disease[J].
Annu Rev Med, 2023, 74:261-277. DOI: 10.1146/annurev-med-
043021-032816.
[9] Xu Y, Alfaro-Magallanes VM, Babitt JL. Physiological and
pathophysiological mechanisms of hepcidin regulation: clinical
implications for iron disorders[J]. Br J Haematol, 2021,
193(5):882-893. DOI: 10.1111/bjh.17252.
[10] Adams PC, Jeffrey G, Ryan J. Haemochromatosis[J]. Lancet,
2023, 401(10390): 1811-1821. DOI: 10.1016/S0140-6736(23)
00287-8.
[11] Griffiths WJH, Besser M, Bowden DJ, et al. Juvenile
haemochromatosis[J]. Lancet Child Adolesc Health, 2021,
5(7):524-530. DOI: 10.1016/s2352-4642(20)30392-8.
[12] Kong X, Xie L, Zhu H, et al. Genotypic and phenotypic
spectra of hemojuvelin mutations in primary hemochromatosis
patients: a systematic review[J]. Orphanet J Rare Dis, 2019,
14(1):171. DOI: 10.1186/s13023-019-1097-2.
[13] Hamdi-Roze H, Ben Ali Z, Ropert M, et al. Variable
expressivity of HJV related hemochromatosis: "Juvenile"
hemochromatosis?[J]. Blood Cells Mol Dis, 2019, 74: 30-33.
doi: 10.1016/j.bcmd.2018.10.006.
[14] Huang FW, Rubio-Aliaga I, Kushner JP, et al. Identification of
a novel mutation (C321X) in HJV[J]. Blood, 2004, 104(7):
2176-2177. DOI: 10.1182/blood-2004-01-0400.
[15] 李元丰, 张红星, 张海涛, 等 . 一个中国遗传性血色病家系致
病基因的突变分析[J]. 遗传, 2014, 36(11):1152-1158. DOI:
10.3724/SPJ.1005.2014.1152.
[16] Li SF, Xue J, Chen BJ, et al. Two middle-age-onset
hemochromatosis patients with heterozygous mutations in the
hemojuvelin gene in a Chinese family[J]. Int J Hematol, 2014,
99(4):487-492. DOI: 10.1007/s12185-014-1547-5.
[17] Biasiotto G, Carini M, Bresciani R, et al. Hereditary
hemochromatosis: the complex role of the modifier genes[J]. J
Trace Elem Med Biol, 2023, 79:127248. DOI: 10.1016/j.jtemb.
2023.127248.
[18] Deugnier Y, Morcet J, Laine F, et al. Reduced phenotypic
expression in genetic hemochromatosis with time: role of
exposure to non-genetic modifiers[J]. J Hepatol, 2019, 70(1):
118-125. DOI: 10.1016/j.jhep.2018.09.009.
[19] Zhang W, Li Y, Xu A, et al. Identification of novel non-HFE
mutations in Chinese patients with hereditary hemochromatosis[J].Orphanet J Rare Dis, 2022, 17(1):216. DOI: 10.1186/s13023-022-02349-y.
[20] Cartella I, Tavecchia GA, Quattrocchi G, et al. A heart of iron:juvenile haemochromatosis presents with cardiac failure[J].
Lancet, 2022, 400(10352):616. DOI: 10.1016/s0140-6736(22)
01285-5.
[21] 汤珊, 郑素军, 段钟平 . 欧洲肝病学会《血色病临床实践指
南 》推荐 意 见 [J]. 中华 肝 脏 病 杂 志 , 2022, 30(9): 934-938.
DOI: 10.3760/cma.j.cn501113-20220717-00384.
[22] Crawford DHG, Ramm GA, Bridle KR, et al. Clinical practice
guidelines on hemochromatosis: Asian Pacific Association for
the Study of the Liver[J]. Hepatol Int, 2023, 17(3): 522-541.
DOI: 10.1007/s12072-023-10510-3.
[23] 张伟, 黄坚, 欧晓娟, 等 . 血色病国际有关HFE p.Cys282Tyr 纯
合基因型血色病的治疗推荐意见[J]. 中华肝脏病杂志, 2019,
27(12):980-981. DOI: 10.3760/cma.j.issn.1007-3418.2019.12.009.
[24] Milman N, Pedersen P, Steig Tá, et al. Clinically overt
hereditary hemochromatosis in Denmark 1948-1985: epidemiology,factors of significance for long-term survival, and causes of death in 179 patients[J]. Ann Hematol, 2001, 80(12):737-744.DOI: 10.1007/s002770100371.
[25] Prabhu A, Cargill T, Roberts N, et al. Systematic review of the clinical outcomes of iron reduction in hereditary hemochromatosis[J]. Hepatology, 2020, 72(4):1469-1482. DOI: 10.1002/hep.31405.
